Clinical Trial Update: Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating LB-LR1109 alone and in combination with atezolizumab for solid tumors, including non-small cell lung cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Malignant Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• LB-LR1109 (LB-LR1109)

Snippet

Sponsor: LG Chem | Conditions: Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC) | Phase 1 | Status: RECRUITING